24. Ulusal Biyokimya Kongresi - TÃ¼rk Biyokimya Dergisi

More documents

Recommendations

Info

XXIV. ULUSAL B‹YOK‹MYA KONGRES‹ 25 - 28 Eylül 2012 Dedeman Otel - Konya 24. Ulusal Biyokimya Kongresi, Konya [24 th National Biochemistry Congress, Konya / TURKEY] İÇİNDEKİLER P115 - SELEKTİF RXR LİGANDININ TİROİD KANSERİ HÜCRE HATLARI ÜZERİNDE ANTİKANSER ETKİNLİĞİ 1 Pınar Kemanlı, 1 Fırat Soyarat, 2 Hilal Koçdor, 3 Halil Ateş, 4 Fırat Bayraktar, 5 Özhan Özdoğan, 6 Hayri Özsan, 7 Mehmet Ali Koçdor 1 Dokuz Eylül Üniversitesi Sağlık Bilimleri Enstitüsü, Moleküler Tıp AD, İZMİR 2 Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, Temel Onkoloji AD, İZMİR 3 Dokuz Eylül Üniversitesi Tıp Fakültesi, Hematoloji, İZMİR 4 Dokuz Eylül Üniversitesi Tıp Fakültesi, Endokrinoloji AD, İZMİR 5 Dokuz Eylül Üniversitesi Tıp Fakültesi, Nükleer Tıp AD, İZMİR 6 Dokuz Eylül Üniversitesi Tıp Fakültesi, Hematoloji BD, İZMİR 7 Dokuz Eylül Üniversitesi Tıp Fakültesi, Genel Cerrahi AD, İZMİR P115 - ANTICANCER EFFICACY OF SELECTIVE RXR LIGAND ON THYROID CANCER CELL LINES 1 Pınar Kemanlı, 1 Fırat Soyarat, 2 Hilal Koçdor, 3 Halil Ateş, 4 Fırat Bayraktar, 5 Özhan Özdoğan, 6 Hayri Özsan, 7 Mehmet Ali Koçdor 1 Molecular Medicine, Dokuz Eylul University Institute Of Health Science, İZMİR 2 Basic Oncology, Dokuz Eylul University Institute Of Oncology, İZMİR 3 Hematology, Dokuz Eylul University Faculty Of Medicine, İZMİR 4 Endocrinology, Dokuz Eylul University Faculty Of Medicine, İZMİR 5 Nuclear Medicine, Dokuz Eylul University Faculty Of Medicine, İZMİR 6 Hematology, Dokuz Eylul University Faculty Of Medicine, İZMİR 7 General Surgery, Dokuz Eylul University Faculty Of Medicine, İZMİR CONTENTS Tiroid karsinomları endokrin sistemin en sık görülen malignitesidir ve özellikle diferansiye karsinomların insidansı (papiller ve folliküler) progresif bir artış göstermektedir. Cerrahi ve radyoiyot uygulamaları bu türlerin ana tedavi şeklidir. Diferansiyasyonun azalması ya da kaybı prognozu kötüleştirmekte, radyoiyot tedavilere direnci artırmaktadır. Spesifik sentetik reksinoid beksaroten, tek başına ya da diğer retinodilerle birlikte kullanıldığında, hücreleri diferansiye edici potansiyele sahiptir. Örneğin tiroid kanser hücrelerinin radyoaktif iyot alımını artırabilecek aşamaya getirebilmektedir. Ancak, beksarotenin kendi başına anti-kanser etkinliği belirgin değildir. Çalışmamızda, RXR selektif ligandı beksarotenin far Thyroid cancer is the most common malignant tumor of the endocrine system and incidence of differentiated carcinomas (papillary and follicular) increase progressively in particular. Differentiated tumors are often curable with surgical resection and radioactive iodine ablation therapy. Reduction or loss of differentiation worsens prognosis, increases resistance to radioiodine therapy. Spesific synthetic rexinoid bexarotene has redifferentiating potential on cells when treated alone or with other retinoids. For instance thyroid cancer cells can be come back to the stage of taking radioactive iodine again. However, it is not clear that bexarotene has anticancer efficacy alone. The aim of this study is to determine that selective RXR ligand bexarotene has anticancer efficacy of inducing apoptosis, modulating cell cycle and detection of efficient inhibitor dose concentration (IC50) on viability of different thyroid cancer cell lines (BCPAP, CGTH W-1, 8505C, CAL-62). Bexarotene has effect of increased early-late apoptosis, especially G1 and Sub-G1 arrest and necrotic cell ratio with detected efficient concentrations on all cell lines. In conclusion, it has been determined that selective RXR ligand Bexarotene has anticancer potantial on differentiated, poorly differentiated and anaplastic (undifferentiated) thyroid cancers and nuclear RXR receptors can be target for therapy of thyroid cancer. Turk J Biochem, 2012; 37 (S1) http://www.TurkJBiochem.com
XXIV. ULUSAL B‹YOK‹MYA KONGRES‹ 25 - 28 Eylül 2012 Dedeman Otel - Konya 24. Ulusal Biyokimya Kongresi, Konya [24 th National Biochemistry Congress, Konya / TURKEY] İÇİNDEKİLER P116 - MCF-7 MEME KANSERİ HÜCRE PROLİFERASYONUNA D VİTAMİNİNİN ETKİSİ 1 Emine Nedime KORUCU, 1 Ali ÜNLÜ, 1 Gülsüm TEKIN, 1 Bahadır ÖZTÜRK 1 Selçuk/Selçuklu Tıp, Tıbbi Biyokimya, Konya P116 - THE EFFECT OF VİTAMİN D ON MCF-7 CELL LİNE PROLİFERATİON 1 Emine Nedime KORUCU, 1 Ali ÜNLÜ, 1 Gülsüm TEKIN, 1 Bahadır ÖZTÜRK 1 Medical Biochemistry, Selçuk/Selçuklu Medical Faculty, Konya CONTENTS Giriş: Vitamin D, kemik metabolizması, immun cevabın düzenlenmesinde, hücre proliferasyonu ve diferansiasyonunun düzenlenmesinde ve bu durumlarla ilişkili birçok hastalıkla (osteoartirit, diabet, kanser, kardiovasküler hastalıklar, tuberküloz) doğrudan ilişkili olduğu belirtilmektedir. D vitamini hücre siklusu ve hücre büyümesinin regülasyonu, hücresel diferansiasyon, apopitozis, immün modulasyon, hormonal entegrasyon, hücresel sinyal yollarını da içeren farklı biyolojik aktivitelerde kritik rolleri olan steroid bir hormondur. 1,25 (OH) 2D3’ün hem normal hem de kanser hücresi proliferasyonunu inhibe ettiği belirtilmektedir. Biz bu çalışmada in vitro vitamin D’nin farklı konsantrasyonlarının invaziv meme kanser hücresi olan MCF-7 proliferasyonuna etkisini araştırmayı amaçladık. Metod: Çalışmada MCF-7 hücre hattındaki proliferasyona D vitaminin farklı dozlarının (1, 5, 10, 25, 50, 75, 100 µM) etkisini değerlendirmek için gerçek zamanlı hücre analizörü (xCELLigence, Roche Diagnostics GmbH, Penzbeerg, Germany) kullanıldı. 10.000 hücre/well E-plate 16®’nın her bir kuyusuna ekildi. Hücre sayısındaki değişiklikler 138 saat boyunca her 15 dk da bir analiz edilmiştir. İstatistik analizinde, kontrol ve farklı dozların karşılaştırılmasında tek yönlü varyans analizi ile, ikincil karşılaştırmalar Tukey HSD ile yapıldı. Anlamlılık seviyesi 0,05 olarak alındı. Bulgular: Doz grupları arasındaki farklılık tedavinin 96. saatinde anlamlı bulundu. (p:0,000 ) 50, 75,100 µM konsantrasyonda vitamin D nin antiproliferatif etkisi gözlendi. Hücre proliferasyonunu sırasıyla %47,86 ve %23,8 inhibe etti ve 48. saatte inhibisyon başladı. 50 µM vitamin D 96. saatte %92,54 hücre proliferasyonunu inhibe etti. Sonuç: Çalışmada; 50, 75,100 µM konsantrasyonlarında MCF-7 hücre hattında zamana ve doza bağımlı vitamin D nin antiproliferatif etkisi gözlendi. Introduction: The vitamin D is involved in a wide variety of biological processes including bone metabolism, modulation of the immune response, regulation of cell proliferation and differentiation regulation. Thus, it has been linked to several common diseases, including osteoarthritis, diabetes, cancer, cardiovascular disease and tuberculosis. Vitamin D is a steroid hormone which is able to regulate of cell cycle and cellular proliferation and differentiation, apoptosis, immune modulation, hormonal integration, including cellular signaling pathways, critical roles in different biological activities. In this study we aimed to investigate the effect of diffent vitamin D concentrations on to invasive breast cancer MCF- 7 cell proliferation. Methods: A real-time cell analyzer (xCELLigence, Roche Diagnostics GmbH, Penzbeerg, Germany) was used to evaluate the effects of different doses of vitamin D (1 to 100 µM) on the proliferation of MCF–7 cell line. 10,000 cells/well were seeded into the each wells of E-plate 16®. The changes of cell number was analyzed every 15 minutes for 138 hours. Comparisons between groups were performed by one way ANOVA. Tukey HSD comparisons were performed with a binary. Significant level was taken 0,05. Results: Accordingly, the difference between dose groups was found significant after treatment for 96 hours (P:0,000). An antiproliferative effect of vitamin D was observed with 50, 75, 100 µM in MCF–7 cells. In 100 and 75 µM concentrations inhibited cell proliferation by %47,86 and % 23,8 respectively and inhibition started at 48th hour. 50 µM vitamin D inhibited cell proliferation by %92,54 and inhibition started at 96th hour. Conclusion: The results of this study demonstrated that antiproliferative effects of vitamin D was observed with 50, 75 and 100 µM concentrations in a time and dose-dependent manner on MCF–7 cells. Turk J Biochem, 2012; 37 (S1) http://www.TurkJBiochem.com
Page 1 and 2:
XXIV. ULUSAL B‹YOK‹MYA KONGRES
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206: XXIV. ULUSAL B‹YOK‹MYA KONGRES
Page 255: XXIV. ULUSAL B‹YOK‹MYA KONGRES
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
show all

24. Ulusal Biyokimya Kongresi - TÃ¼rk Biyokimya Dergisi

Create successful ePaper yourself

Delete template?

Save as template?